NASDAQ:SVRA   Savara, Inc.
Sector: Health Technology
Industry: Biotechnology
Savara, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its products include AeroVanc, Molgradex, GM-CSF, and Aironite. The company was founded on April 27, 2017 and is headquartered in Austin, TX.

Market Capitalization
115.522M

Total Shares Outstanding (MRQ)
54.236M

Net Debt (MRQ)
-56.821M

Total Assets (MRQ)
97.745M

Revenue per Employee (TTM)
9518.5185

Free Cash Flow (TTM)
-39.883M :(, but it's BIO and other indicators look good.

Phase 2-3 trials, FDA looking at turning decision from June that scared off investors.

Analyst upgrade to 7
면책사항

이 정보와 게시물은 TradingView에서 제공하거나 보증하는 금융, 투자, 거래 또는 기타 유형의 조언이나 권고 사항을 의미하거나 구성하지 않습니다. 자세한 내용은 이용 약관을 참고하세요.